Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757725

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757725

Fatty Liver Treatment

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Fatty Liver Treatment Market to Reach US$23.1 Billion by 2030

The global market for Fatty Liver Treatment estimated at US$18.7 Billion in the year 2024, is expected to reach US$23.1 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Thiazolidinedione, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Vitamin E segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 6.5% CAGR

The Fatty Liver Treatment market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Fatty Liver Treatment Market - Key Trends & Drivers Summarized

Why Is Fatty Liver Disease Becoming a Major Global Health Concern Necessitating Targeted Treatments?

Fatty liver disease, encompassing both non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), has emerged as a critical public health issue worldwide due to its rising prevalence, close association with metabolic disorders, and potential to progress into more severe hepatic conditions such as steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Modern sedentary lifestyles, poor dietary habits, rising obesity rates, and increased incidence of type 2 diabetes have all contributed to an alarming increase in fatty liver diagnoses, particularly NAFLD, which now affects up to 25% of the global population. Despite its prevalence, fatty liver disease often remains undiagnosed in its early stages due to the lack of symptoms, allowing progression without intervention. As a result, there is growing urgency to develop and implement effective treatment options, ranging from lifestyle modification programs and pharmacologic interventions to surgical solutions in severe cases. Moreover, the potential link between fatty liver disease and cardiovascular complications further elevates its medical significance, making its treatment not only essential for liver health but also for reducing broader systemic risks. As awareness improves among both clinicians and patients, early diagnosis and tailored treatment strategies are becoming crucial in slowing disease progression and reducing long-term healthcare burdens associated with chronic liver diseases.

How Are Therapeutic Innovations Transforming the Management of Fatty Liver Disease?

Advances in medical research and pharmaceutical development are rapidly transforming the landscape of fatty liver treatment, offering hope for more effective disease management and long-term outcomes. Traditionally, lifestyle modifications-such as dietary changes, increased physical activity, and weight loss-have served as the first line of defense against fatty liver disease. However, the limitations of patient adherence and the lack of consistent outcomes have accelerated the pursuit of pharmacologic solutions. Several drug candidates targeting key mechanisms in lipid metabolism, inflammation, fibrosis, and insulin resistance are currently in clinical trials, including FXR agonists, PPAR agonists, and GLP-1 receptor agonists. Drugs like pioglitazone and vitamin E have shown modest success in certain patient subgroups, while newer agents such as obeticholic acid and resmetirom are demonstrating promising results in reducing liver fat content and fibrosis in NASH (non-alcoholic steatohepatitis) patients. In addition to monotherapies, combination therapies that simultaneously address multiple pathogenic pathways are gaining traction as potentially more effective interventions. The integration of non-invasive diagnostic tools such as FibroScan, MRI-PDFF, and serum biomarkers is also enhancing treatment monitoring and enabling personalized care plans. Moreover, digital health tools and mobile health apps are helping patients maintain lifestyle changes through behavior tracking and telemedicine support. These therapeutic innovations are not only improving clinical outcomes but are also making fatty liver treatment more accessible, evidence-based, and adaptable to patient-specific conditions.

Why Is Demand for Fatty Liver Treatments Growing Across Demographics and Geographies?

The demand for effective fatty liver treatments is increasing across all age groups and regions, fueled by the global rise of metabolic syndromes and the growing recognition of fatty liver disease as a silent but serious health threat. While once considered a condition affecting primarily older adults or individuals with a history of alcohol misuse, fatty liver disease is now being diagnosed in younger populations-including children and adolescents-largely due to increasing rates of childhood obesity and sedentary lifestyles. In high-income countries like the U.S., Germany, Japan, and the U.K., where processed food consumption and diabetes prevalence are high, NAFLD has become one of the leading causes of chronic liver disease. Meanwhile, emerging economies such as India, China, Brazil, and countries in the Middle East are witnessing a rapid surge in cases due to urbanization, dietary shifts, and lifestyle transitions-often outpacing healthcare system preparedness. These demographic shifts are creating immense pressure on healthcare providers to adopt early screening protocols, allocate resources for public health education, and expand treatment access. Additionally, rising awareness through public health campaigns, online platforms, and physician advocacy is prompting more individuals to seek diagnostic evaluations and therapeutic interventions. Pharmaceutical companies and healthcare institutions are responding by ramping up clinical research, regional partnerships, and educational outreach to address this growing and geographically widespread patient population. This global rise in disease burden is not only expanding the treatment market but also encouraging collaboration across stakeholders to develop scalable and sustainable solutions.

What Are the Primary Drivers Fueling the Growth of the Fatty Liver Treatment Market Worldwide?

The growth of the fatty liver treatment market is being driven by a multifaceted set of clinical, economic, technological, and policy-related factors that together reflect the urgency and complexity of managing this rising health challenge. A key driver is the escalating prevalence of lifestyle-related diseases such as obesity, diabetes, and metabolic syndrome, all of which are strongly linked to the onset and progression of fatty liver disease. The lack of FDA-approved therapies specifically for NAFLD and NASH has created a massive unmet medical need, fueling robust investment in drug development and clinical research. Advances in biomarker discovery, imaging technologies, and artificial intelligence are enabling earlier diagnosis, risk stratification, and treatment optimization, significantly enhancing patient outcomes and health system efficiency. Health insurance providers and public healthcare systems are increasingly recognizing the long-term cost burden of untreated fatty liver disease, prompting broader reimbursement for non-invasive testing and emerging therapies. Regulatory agencies are also accelerating approval timelines for promising drug candidates, spurred by the urgent need for intervention. Strategic collaborations between biopharmaceutical firms, academic institutions, and diagnostic companies are expanding the innovation pipeline and reducing time-to-market for novel treatments. Furthermore, increased public awareness, patient advocacy efforts, and digital engagement platforms are empowering individuals to take a proactive role in liver health management. Combined, these factors are setting the stage for significant and sustained expansion of the global fatty liver treatment market, transforming a once-overlooked condition into a major focus of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Fatty Liver Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers, Pentoxifylline); End-Use (Hospitals, Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Echosens
  • Enanta Pharmaceuticals
  • Genfit
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Inventiva
  • Madrigal Pharmaceuticals
  • Merck & Co.
  • NGM Biopharmaceuticals
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Praxis Precision Medicines
  • Sanofi
  • Viking Therapeutics
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35045

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Fatty Liver Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of NAFLD and NASH Throws the Spotlight on Fatty Liver Drug Development
    • Obesity and Diabetes Epidemic Propels Growth in Demand for Metabolic and Hepatic Therapies
    • Absence of FDA-Approved NASH Drugs Expands Addressable Market for Novel Therapeutics
    • Focus on Fibrosis Prevention and Reversal Strengthens the Business Case for Anti-Fibrotic Agents
    • Push Toward Combination Therapy Approaches Accelerates Innovation in Multi-Target Drug Pipelines
    • Advancements in Non-Invasive Diagnostic Tools Support Early Intervention and Treatment Expansion
    • Patient Stratification and Biomarker Development Enhance Precision in Therapeutic Targeting
    • Lifestyle and Behavioral Health Integration Spurs Demand for Complementary Digital Health Solutions
    • High Prevalence in Aging Population Sustains Growth in Demand for Long-Term Liver Health Management
    • Expanding Role of Genomic and Epigenetic Research Drives Innovation in Mechanism-Based Drug Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fatty Liver Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fatty Liver Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Thiazolidinedione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Thiazolidinedione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Thiazolidinedione by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vitamin E by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vitamin E by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vitamin E by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metformin Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metformin Statins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metformin Statins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Polyunsaturated Fatty Acids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Polyunsaturated Fatty Acids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Polyunsaturated Fatty Acids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Angiotensin Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pentoxifylline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pentoxifylline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pentoxifylline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • JAPAN
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • CHINA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • EUROPE
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Fatty Liver Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • FRANCE
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • GERMANY
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Fatty Liver Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • INDIA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Fatty Liver Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Fatty Liver Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Fatty Liver Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030
  • AFRICA
    • Fatty Liver Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Fatty Liver Treatment by Drug - Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Fatty Liver Treatment by Drug - Percentage Breakdown of Value Sales for Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers and Pentoxifylline for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Fatty Liver Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Fatty Liver Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Fatty Liver Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!